Levodopa Elevates Homocysteine: Is This a Problem?

Archives of Neurology

Volumn 61, Issue 5, 2004, Pages 633-634

  O'Suilleabhain, Padraig ^a   Diaz Arrastia, Ramon ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSYLHOMOCYSTEINASE; CATECHOL METHYLTRANSFERASE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; S ADENOSYLMETHIONINE; VITAMIN B GROUP;

ALZHEIMER DISEASE; BLOOD LEVEL; DEMENTIA; DEPRESSION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; EDITORIAL; HIGH RISK PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SENSORY NEUROPATHY; STROKE;

ANTIPARKINSON AGENTS; BRAIN; HOMOCYSTEINE; HUMANS; LEVODOPA; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; S-ADENOSYLMETHIONINE;

EID: 2442486956     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.5.633     Document Type: Editorial

References (17)

1. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol. 2000;57:1422-1427.
2. Bolander-Gouaille C, Bottiglieri T. Homocysteine, Related Vitamins, and Neuropsychiatric Disorders. Paris, France: Springer-Verlag; 2003.
3. Jacobsen DW. Cellular mechanisms of homocysteine pathogenesis in atherosclerosis. In: Carmel R, Jacobsen DW, eds. Homocysteine in Health and Disease. Cambridge, England: Cambridge University Press; 2001:425-440.
4. Allain P, Le Bouil A, Cordillet E, Le Quay L, Bagheri H, Montastruc JL. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology. 1995;16:527-529.
5. Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol. 1998;40:225-227.
6. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet. 1999;354:126-127.
7. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology. 2000;55:437-440.
8. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology. 2003;60:1125-1129.
9. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand. 2003;108:66-67.
10. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol. 2003;60:59-64.
11. Nakaso K, Yasui K, Kowa H, et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-OOPA, homocysteine, and MTHFR genotype. J Neurol Sci. 2003;207:19-23.
12. Müller T, Renger K, Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol. 2004;61:657-660.
13. Koller W. Sensory symptoms in Parkinson's disease. Neurology. 1984;34:957-959.
14. Korten A, Lodder J, Vreeling F, Boreas A, van Raak L, Kessels F. Stroke and idiopathic Parkinson's disease: does a shortage of dopamine offer protection against stroke? Mov Disord. 2001;16:119-123.
15. Jellinger KA. Prevalence of stroke in Parkinson's disease. Mov Disord. 2003;18:723-724.
16. Rajput AH, Offord KP, Beard CM, Kurland LT. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology. 1987;37:226-232.
17. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.